OncoTherapy Science, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Narrows

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Feb 7, 2025 5:00 pm JST Earnings

4564 OncoTherapy Science, Inc. 【J-GAAP】

Earnings Report

OncoTherapy Science, Inc. <4564> [TSE Growth] announced its financial results after the market closed on February 7th (17:00). The consolidated net loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) was a reduced loss of 717 million yen (compared to a loss of 987 million yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the consolidated net loss improved to a deficit of 172 million yen (compared to a loss of 277 million yen in the same period last year). The operating profit/loss margin drastically improved from -252.7% in the same period last year to -49.4%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	699	-904	-928	-913	-4.7	ー	Feb 10, 2023	J-GAAP
Apr - Dec, 2023	466	-972	-986	-987	-4.7	ー	Feb 9, 2024	J-GAAP
Apr - Dec, 2024	563	-698	-716	-717	-2.8	ー	Feb 7, 2025	J-GAAP
YoY	+20.8%	+28.2%	+27.4%	+27.4%	+40.6%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	254	-426	-428	-578	-2.7	0	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	ー	ー	ー	ー	－	0	May 10, 2024	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	1,134	-1,106	-1,133	-1,118	-5.8	0	May 12, 2023	J-GAAP
Mar, 2024	610	-1,120	-1,136	-1,288	-6.1	0	May 10, 2024	J-GAAP
Mar, 2025 Guidance	ー	ー	ー	ー	－	0	May 10, 2024	J-GAAP
YoY	－	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	110	-278	-278	-277	-1.3	-252.7	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	144	-148	-150	-301	-1.4	-102.8	May 10, 2024	J-GAAP
Apr - Jun, 2024	100	-290	-302	-302	-1.3	-290.0	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	125	-241	-243	-243	-1.0	-192.8	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	338	-167	-171	-172	-0.7	-49.4	Feb 7, 2025	J-GAAP
YoY	+207.3%	+39.9%	+38.5%	+37.9%	+48.9%